Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.
Not all reports are available for public preview. For more information, please contact us.
Relyvrio (formerly AMX0035) is an oral fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO). PB is a prescription drug used to treat urea cycle disorders and TURSO (also known as tauroursodeoxycholic acid [TUDCA]) is a widely available non-prescription supplement. Relyvrio is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults…
Beremagene geperpavec is an investigational topical gene therapy proposed for the treatment of open wounds in patients with dystrophic epidermolysis bullosa.
AuroLase is a focal ablation therapy that uses gold nanoparticles and a near-infrared laser to thermally ablate localized prostate cancer.
Tofersen is an investigational antisense oligonucleotide proposed for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene.
A radiolabeled monoclonal antibody targeting tumor antigen B7-H3 in development for intraventricular radioimmunotherapy for treatment of neuroblastoma central nervous system/leptomeningeal metastases.
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of accelerated repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression.
RBX2660 is an investigational microbiota-based ready-to-use enema product for fecal microbiota transplantation proposed to treat recurrent Clostridoides difficile infection.
Etranacogene dezaparvovec (formerly AMT-061) is an investigational recombinant gene transfer therapy product designed to help patients with hemophilia B produce sufficient plasma levels of endogenous coagulation factor IX (FIX). The main therapeutic goal is long-term expression of FIX at levels steady enough to eliminate the need for routine prophylactic replacement therapy w…
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Zio monitors for heart rhythm monitoring in pediatric patients.
Tofersen is an investigational antisense oligonucleotide proposed for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene.